Genetic heterogeneity in patients with pantothenate kinase–associated neurodegeneration and classic magnetic resonance imaging eye‐of‐the‐tiger pattern

We performed a detailed molecular study in two unrelated families with pantothenate kinase–associated neurodegeneration (PKAN) and the specific magnetic resonance imaging (MRI) eye‐of‐the‐tiger pattern. In the first family with classic PKAN, linkage analysis using polymorphic markers from the PANK2 region ruled out linkage with this locus, and no mutation of the PANK2 gene was found. In the second family with atypical PKAN, we identified a novel homozygous C‐to‐T transition at nucleotide 1069 of the PANK2 gene, which resulted in an arginine to tryptophane substitution at codon 357. As far as we are aware, this is the first case of classic PKAN with the specific MRI eye‐of‐the‐tiger pattern not carrying a PANK2 mutation. Therefore, the present observation reinforces the notion of the phenotypic and genetic heterogeneity in PKAN. © 2005 Movement Disorder Society

[1]  J. Jankovic,et al.  Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden‐Spatz syndrome) and pantothenate kinase‐associated neurodegeneration , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  B. Levinson,et al.  Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. , 2003, The New England journal of medicine.

[3]  Shawn K. Westaway,et al.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome , 2001, Nature Genetics.

[4]  M. Onofrj,et al.  Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide , 2000, Journal of Neurology.

[5]  T. Taylor,et al.  Homozygosity mapping of Hallervorden–Spatz syndrome to chromosome 20p12.3–p13 , 1996, Nature Genetics.

[6]  R. Silva,et al.  Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. , 1996, The Journal of clinical psychiatry.

[7]  A. Shapiro,et al.  Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. , 1989, Archives of general psychiatry.

[8]  M. Mesulam,et al.  Treatment of Gilles de la Tourette's syndrome , 1987, Neurology.

[9]  J. Buitelaar,et al.  Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. , 2001, The Journal of clinical psychiatry.

[10]  A. Lang.  Update on the treatment of tics. , 2001, Advances in neurology.

[11]  E. Dooling,et al.  Hallervorden-Spatz syndrome. , 1974, Archives of neurology.